Entera Bio (ENTX) Price & Analysis

Compare

423 Followers

ENTX Stock Chart & Stats

$3.14

-$0.11(-4.20%)

At close: Jan 08 4:00 PM EST

$3.14

-$0.11(-4.20%)

Day’s Range― - ―

52-Week Range$1.50 - $3.22

Previous CloseN/A

Volume29.71K

Average Volume (3M)123.78K

Market Cap

$127.86M

Enterprise Value$70.32M

Total Cash (Recent Filing)$10.86M

Total Debt (Recent Filing)$203.00K

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Mar 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding45,663,380

10 Day Avg. Volume240,874

30 Day Avg. Volume123,776

Financial Highlights & Ratios

PEG Ratio0.43

Price to Book (P/B)9.88

Price to Sales (P/S)440.99

P/FCF Ratio-11.70

Enterprise Value/Market Cap0.55

Enterprise Value/Revenue423.61

Enterprise Value/Gross Profit-10.05K

Enterprise Value/Ebitda-6.66

Forecast

1Y Price Target

$10.00

Price Target Upside218.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Research And DevelopmentEntera Bio recently announced the presentation of a poster entitled 'A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome' at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress, highlighting pharmacokinetic (PK) data relating to its oral GLP-2 analog program.

Preclinical SafetyNo signs of toxicity were observed in the preclinical studies for the OPK-8801003 GLP-2 tablet.

Regulatory ProgressThe FDA agreed to Entera Bio's proposal that the New Drug Application for its lead candidate EB613 would be supported by a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study in women with post-menopausal osteoporosis.

Bears Say

Entera Bio News

Entera Bio presents clinical data from EB613 Phase 2 trial

Entera Bio (ENTX) reported new clinical data from a post-hoc analysis of its Phase 2 trial of EB613,...

17d ago

ENTX

Entera Bio’s Promising Oral Therapies Drive Buy Rating: Analyst Highlights Developments in GLP-2 and EB613 Programs

Entera Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

2M ago

ENTX

Entera Bio announces presentation of PK data for GLP-2 tablet treatment

Entera Bio (ENTX) announced the presentation of a poster titled “A First-in-Class Oral GLP-2 Analog for Treatment of...

2M ago

ENTX

Entera Bio presents data on EB613 in post-menopausal women with osteoporosis

Entera Bio (ENTX) announced data selected for presentation at the American Society for Bone and Mineral Research 2025...

2M ago

ENTX

Entera Bio to present data across three oral peptide programs

Entera Bio (ENTX) announced that the Company will present data across three key programs during September 2025. American...

2M ago

ENTX

Entera Bio’s Promising Phase 3 Study and Market Potential Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Entera Bio, with a price target of...

3M ago

ENTX

Entera Bio Reports Q2 2025 Financial Results and Strategic Progress

Entera Bio ( ($ENTX) ) has released its Q2 earnings. Here is a breakdown of the information Entera...

3M ago

ENTX

Entera Bio Reports Q2 2025 Financial Results

Entera Bio ( ($ENTX) ) has issued an announcement. Entera Bio announced its second quarter 2025 financial results...

3M ago

ENTX

Entera Bio Advances EB613 with FDA Approval

The latest update is out from Entera Bio ( ($ENTX) ). On July 28, 2025, Entera Bio announced...

3M ago

ENTX

Entera Bio receives FDA agreement on BMD as primary endpoint for EB613 study

Entera Bio (ENTX) announced that in a written response to a Type A meeting request, the U.S. Food...

3M ago

ENTX

Entera Bio Elects New Board Member at Annual Meeting

Entera Bio ( ($ENTX) ) has provided an announcement. Entera Bio Ltd. held its 2025 Annual Meeting of...

4M ago

ENTX

Entera Bio announces data for EB613 to be presented at ASBMR 2025

Entera Bio (ENTX) announced that new data exploring the dual actions of EB613 on trabecular and cortical bone...

5M ago

ENTX

Entera Bio, Opko Health announce new in vivo data for OPK-88006

OPKO Health (OPK) and Entera Bio (ENTX) announced that new pharmacologic and pharmacokinetic in vivo data for investigational...

5M ago

OPK

ENTX

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

OPKO Health (OPK) and Entera Bio (ENTX) announced that new pharmacologic and pharmacokinetic in vivo data for investigational...

5M ago

OPK

ENTX

ENTX FAQ

What was Entera Bio Ltd’s price range in the past 12 months?

Entera Bio Ltd lowest stock price was $1.50 and its highest was $3.22 in the past 12 months.

What is Entera Bio Ltd’s market cap?

Entera Bio Ltd’s market cap is $127.86M.

When is Entera Bio Ltd’s upcoming earnings report date?

Entera Bio Ltd’s upcoming earnings report date is Mar 27, 2026 which is in 138 days.

How were Entera Bio Ltd’s earnings last quarter?

Currently, no data Available

Is Entera Bio Ltd overvalued?

According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entera Bio Ltd pay dividends?

Entera Bio Ltd does not currently pay dividends.

What is Entera Bio Ltd’s EPS estimate?

Entera Bio Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Entera Bio Ltd have?

Entera Bio Ltd has 45,663,380 shares outstanding.

What happened to Entera Bio Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Entera Bio Ltd?

Currently, no hedge funds are holding shares in ENTX

Entera Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-82.22%

Trailing 12-Months

Asset Growth

95.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entera Bio Ltd

Entera Bio Ltd. is a biotechnology company engaged in the development of orally delivered large molecule therapeutics. The company primarily operates within the pharmaceutical and biotechnology sectors, focusing on the advancement of oral formulations of injectable drugs. Entera Bio's core products aim to address unmet medical needs in areas like osteoporosis and hypoparathyroidism by providing more convenient oral delivery options for patients.

Entera Bio (ENTX) Earnings & Revenues

Historic Earnings Reports

ENTX Stock 12 Month Forecast

Average Price Target

$10.00

▲(218.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.596923076923077,3.213846153846154,3.8307692307692305,4.447692307692307,5.064615384615385,5.681538461538461,6.298461538461538,6.915384615384616,7.5323076923076915,8.149230769230769,8.766153846153847,9.383076923076922,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.596923076923077,3.213846153846154,3.8307692307692305,4.447692307692307,5.064615384615385,5.681538461538461,6.298461538461538,6.915384615384616,7.5323076923076915,8.149230769230769,8.766153846153847,9.383076923076922,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.98,2.596923076923077,3.213846153846154,3.8307692307692305,4.447692307692307,5.064615384615385,5.681538461538461,6.298461538461538,6.915384615384616,7.5323076923076915,8.149230769230769,8.766153846153847,9.383076923076922,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.87,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >